Paradigm Biopharmaceuticals Ltd. · ASX:PAR
Paradigm Biopharmaceuticals — Investor Presentation (November 2017)
22 slides from Paradigm Biopharmaceuticals's investor presentation, Nov 2, 2017
Slide 1: Investor Presentation
For personal use only Investor Presentation Paul Rennie, CEO & MD November 2017
Slide 2: Disclaimer
Disclaimer For personal use only This document, together with any information communicated by Paradigm Biopharmaceuticals Ltd (known as “Paradigm”, “Paradigm Biopharma” or “the Company”), in any presentation or discussion relating to this document (collectively, “Information”) is confidential, and h
Slide 3: Corporate Overview
Corporate Overview For personal use only Financial information Paradigm Biopharmaceuticals Ltd is an ASX-listed Share price (01-November-17) A$0.36 biotechnology company focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved Number of shares 101.9m drug that has a long track rec
Slide 4: Investment Proposition
Investment Proposition For personal use only Reduce clinical costs and accelerate commercialisation by repurposing a pre-approved drug - 505(b)(2) Very large addressable markets (combined US$37bn+) - Pentosan Polysulfate Sodium (PPS) is a new, multi-acting treatment for osteoarthritis (associate
Slide 5: Drug Repurposing Strategy
Drug Repurposing Strategy For personal use only Much lower cost, accelerated timeline, lower risk and with higher rates of success Lower cost: average development cost of ~US$30-50m compared to US$1.3bn for “de novo” development1 Faster: FDA 505(b)(2) pathway leveraging previous clinical efforts
Slide 6: Board and Management
Board and Management For personal use only High quality Board and management, with top-tier pharmaceutical experience Board and management are renowned leaders in the biopharmaceutical industry, having held senior management positions with top ASX-listed companies, CSL (CSL.ASX) and Mesoblast (MSB
Slide 7: Broad Product Pipeline
Broad Product Pipeline For personal use only 7 Investor Presentation November 2017
Slide 8: Pentosan Polysulfate Sodium
Pentosan Polysulfate Sodium For personal use only PPS has a long safety history and is currently being sold in the US and Europe Pentosan Polysulfate Sodium Ideal biological characteristics Pentosan Polysulfate Sodium (PPS) has been used in humans PPS is an anti-inflammatory and an anti-histamin
Slide 9: Osteoarthritis and acute joint injuries with BMEL
Osteoarthritis and acute joint injuries with BMEL Currently no approved treatments for Osteoarthritis growing market opportunity For personal use only What are bone marrow edema lesions (BMEL or bone bruising)? Bone marrow edema lesions or bone bruising is the accumulation of interstitial fluid or
Slide 10: Osteoarthritis with BMEL: The Market for ZILOSUL
Osteoarthritis with BMEL: The Market for ZILOSUL® ZILOSUL® has the potential to fill the current gap in osteoarthritis treatment options For personal use only There is currently no effective treatment for osteoarthritis and bone marrow edema lesions that treats the underlying pathology of the dise
Slide 11: Osteoarthritis with Bone Marrow Edema Lesions
Osteoarthritis with Bone Marrow Edema Lesions TGA Special Access Scheme – Real World Evidence – First 24 patients treated For personal use only All patients (median age of 57.5 years - range 31 to 84 years) had pain and failed current standard of care - analgesics, NSAIDs or corticosteroids. At six
Slide 12: OA with BMEL: Clinical Timeline
OA with BMEL: Clinical Timeline Status update For personal use only OA/BMEL case study published in peer reviewed scientific journal 10 participants treated under the Phase 2a open label clinical trial - close-out expected Oct/Nov 2017 Trial investigating the safety, tolerability and efficacy
Slide 13: Viral Arthritis – Alphavirus
Viral Arthritis – Alphavirus No approved treatment for severely debilitating virus infection For personal use only Viral Arthritis Alphavirus infections result in the clinical symptoms of joint and muscle pain, fever and joint inflammation. Ross River Virus (RRV) and Chikungunya (CHIKV) are mosq
Slide 14: Viral Arthritis: Clinical Timeline
Viral Arthritis: Clinical Timeline Potential to gain Orphan status, resulting in fast-tracked clinical development For personal use only Pre-clinical studies have been conducted by the Institute of Glycomics at Griffith University. The results suggested that: − PPS significantly alleviated the sev
Slide 15: IL-1RA Peptide
IL-1RA Peptide For personal use only Safe and Stable Treatment for Multiple Indications What is IL-1RA Peptide? Vended in during the Initial Public Offering A novel IL-1RA peptide antagonist (“IP1510”), consists of D-amino Inflammatory Bowel Disease acids with reversed peptide sequence (a retro-
Slide 16: Heart Failure
Heart Failure For personal use only Desperate need for new effective treatments to stabilise & reverse heart degeneration What is Heart Failure? Heart failure is a chronic, progressive condition in which the Addressable market for Heart Failure: heart muscle is unable to pump enough blood through
Slide 17: Respiratory Conditions - Hay Fever
Respiratory Conditions - Hay Fever Hay fever is a very common condition that is poorly treated at present For personal use only What is hay fever (allergic rhinitis)? Allergic inflammation of the nasal airways, when an allergen is inhaled by a sensitised individual Addressable market for hay fever
Slide 18: IP Protection
IP Protection For personal use only Multi-faceted IP protection increases barriers to entry for potential competitors Valuable patent portfolio Paradigm has patent protection because it is using PPS for new indications Minimum life on patents is 2030 and beyond for more BMEL patent granted in EU
Slide 19: Peer Comparison
Peer Comparison For personal use only Attractive investment given low risk development and large market opportunity Paradigm appears undervalued compared to similar stage, drug repurposing peers given its platform for successful development, secure industrial scale manufacturing and the size of it
Slide 20: Global Big Pharma Interest
Global Big Pharma Interest Recent transactions highlight big pharma interest in BMEL/OA, Heart failure and IBD For personal use only Date ↓ Target Acquirer Deal value (US$) Relevance Galapagos licensed GLPG1972, a potential disease- modifying oral therapy for osteoarthritis to Servier Jul - 17 $34
Slide 21: Share Price Catalysts
Share Price Catalysts Upcoming milestones should drive strong shareholder returns For personal use only Phase 2a open label trial for BMEL with ACL injuries OA with BMEL RWE results (second 25 patients followed by 2 x 25 patients over year) ACL/BMEL Recruit Phase 2b placebo controlled OA clini
Slide 22: Contacts
Contacts For personal use only Office Level 2, 517 Flinders Lane, Melbourne, VIC, 3000 info@paradigmbiopharma.com Managing Director & CEO Paul Rennie - prennie@paradigmbiopharma.com Chief Scientific Officer Dr Ravi Krishnan – rkrishnan@paradigmbiopharma.com Corporate Advisor Baker Young Stockbrokers
Paradigm Biopharmaceuticals — Investor Presentation (November 2017) on 6ix